Directory · JP
Biotechnology Research in Japan
A register of firms and the professionals working at them in the Biotechnology Research sector based in Japan. Browse the public index, then filter or export on Kipplo.
Companies
225 on file
Alnylam Pharmaceuticals
SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe,+31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."
1001 to 5000 staff
Pharmaessentia
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan, leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology, and immunology. Founded in 2003, PharmaEssentia is now expanding its global presence with operations in the U.S, Japan, China and Korea.
501 to 1000 staff
Active Motif
What is exciting about the area we work in? Epigenomics is the systematic analysis of the global state of gene expression not attributable to mutational changes across the entire genome. Epigenetic mechanisms are affected by external factors including development in utero and in childhood, environmental chemicals, drugs and pharmaceuticals, aging, and diet. Changes to the epigenetic landscape can have a profound impact on health and disease. Precise mapping and measurement of the epigenetic landscape offers the promise of predictive biomarkers of disease development, even before changes in gene expression have taken place. Epigenomics is the “OME” connecting Genomics to Transcriptomics and Proteomics allowing a Multiomics approach to disease research which will result in a higher yield of data that can be aggregated and analyzed to become actionable information. What does Active Motif offer? Epigenetic methods and approaches require the use of high-quality antibodies and enzymes that have undergone strict validation criteria. This allows the development of robust assays for use in mechanistic studies, translational medicine, drug discovery and diagnostics. Active Motif’s Product Development Program takes emerging novel techniques, and develops them into innovative products that allow researchers to perform the assays in their own labs as well as feeding into their end to end services pipeline. Active Motif is building a platform based on their patented transposase based technologies to simplify the interrogation of chromatin, the dynamics of histone modifications, chromatin remodeling, DNA methylation, transcription factor binding, as well as short and long range gene regulation by non-coding regulatory regions. Our bioinformatics platform can take the data generated by these techniques and provide powerful insights into the epigenetic changes occurring in disease or in response to drugs.
51 to 200 staff
Cardurion Pharmaceuticals
Cardurion Pharmaceuticals is a next generation cardiovascular company focused on the discovery and development of novel therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by an experienced team of CV experts and industry veterans, we are developing groundbreaking clinical programs in PDE9 and CaMKII inhibition. We take a strategic portfolio approach driven by in-house drug discovery and our office of strategy and have concluded foundational partnerships with key strategics and investors, including an up to $300 million dollar investment from Bain Capital to support current programs and pipeline growth. Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at
11 to 50 staff
Mbf Bioscience
We create scientific hardware solutions for light sheet and multiphoton microscopy, fiber photometry, and whole slide imaging. Specializing in integrated quantitative image analysis software for stereology, brain mapping, neuron and vessel morphology, we empower researchers to push the boundaries of discovery.
51 to 200 staff
The Jackson Laboratory
OVERVIEW • The Jackson Laboratory is an independent, 501(c)3 nonprofit biomedical research institution founded in 1929 in Bar Harbor, Maine. • Our mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. • We are a global team of nearly people at 11 locations in Maine, Connecticut, California, Japan and China, and in remote locations around the world. • With a 2023 operating budget of $628M, JAX has substantial impact on our local communities. RESEARCH • With more than 60 faculty members, our diverse and multidisciplinary research programs include the National Cancer Institute-designated JAX Cancer Center, as well as coordinated research centers focused on addiction, aging, Alzheimer’s and dementias, genomics and computational biology, precision genetics and rare disease. • JAX has had a National Cancer Institute-designated Cancer Center since 1983, and is one of only seven institutes in the United States that has received this designation for its contributions to basic cancer research. • Our researchers have made significant contributions to medical progress, including bone marrow and organ transplants, stem cell therapies and in vitro fertilization. EDUCATION • We offer comprehensive educational programs for scientists throughout their careers, from high school students and teachers, to researchers at all experience levels, and for clinical providers interested in incorporating genetics and genomics into their practices. RESOURCES • Over 2,400 organizations in 68 countries rely on over strains of genetically-specialized JAX® Mice and research services in a wide range of therapeutic areas. • Our Mouse Genome Informatics database is the world’s source for information on mouse genetics and biology.
1001 to 5000 staff
Kewpie Fine Chemical
This is Kewpie Fine Chemical official account. Our main products are raw materials (Sodium hyaluronate, Egg yolk lecithin, Eggshell membrane, etc.) for pharmaceuticals, cosmetics and foods. These contents are mainly for business persons and researchers, and also have announcements of exhibitions. Sorry, we do not respond to your comment on our posts basically. If you have any questions, please contact us using the form below!
10001+ staff
Huyabio International
HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.
51 to 200 staff
Jcr Pharmaceuticals
JCR Pharmaceutical is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S, Europe, and Latin America. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We are leaders in developing therapies for rare conditions, including lysosomal storage disorders (LSDs). We are building on the development work we've done in Japan to expand our LSD pipeline: Our first-in-class proprietary technology, J-Brain Cargo®, enables us to develop therapies that cross the blood-brain barrier and penetrate the central nervous system (CNS). The CNS complications of diseases are often severe, resulting in developmental delays, an impact on cognition and, above all, poor prognosis, which affect patients' independence as well as the quality of life of patients and their caregivers. With J-Brain Cargo®, we seek to address the unresolved clinical challenges of LSDs and CNS-related disorders, including neurodegeneration, neuro-oncology, and neuro-inflammation conditions, by delivering the therapy to both the body and the brain. We will continuously try to create value by our unique J-Brain Cargo® technology platform toward our corporate philosophy: We create treatments that go beyond rare disease to solve the world's most complex healthcare challenges. In addition to the in-house research activities, we think collaborative research and development work with other companies are also important. The value of our technology platforms will be increased by integrating ours with other technologies and by implementing J-Brain Cargo® and JUST-AAV within other companies’ products.
501 to 1000 staff
Molcure Inc
MOLCURE was founded in 2013 with a mission to build the best platform for biologics discovery in the world. Today, its platform integrates AI with evolutionary molecular engineering, next-generation sequencing, laboratory automation technologies, and a proprietary database containing more than one billion molecular entries. These capabilities enable the delivery of diverse, high affinity, specific, and functional antibodies and peptides for researchers. MOLCURE is partnering with innovative companies to discover therapeutics with the potential to benefit patients around the world.
11 to 50 staff
Adinstruments
ADInstruments is committed to providing innovative tools for research and education. Our company helps scientists and educators achieve their goals with our industry-leading PowerLab and LabChart data acquisition systems. Since 1988, life science research has been and continues to be a key driver for innovation in our research product line. Today, approximately ADInstruments data acquisition systems are used worldwide in research and teaching. Our newest and most innovative product, Lt, takes education a step further with its cloud-based learning platform and over 900 pre-configured courses in physiology, biology, medicine, and nursing. ADInstruments is a brand synonymous with elegant research and education solutions tailored to suit, and our commitment to our customers is unmatched in our industry.#MakingScienceEasier
51 to 200 staff
Algal Bio
Our principal mission is to cultivate algae's potential based on our unique capabilities built upon our access to approximately algae strains. Our unique capabilities with proprietary breeding technology, strain screening capability and cultivation expertise will put us in a unique position unlocking algae's potential for a better future.
11 to 50 staff
Modalis Therapeutics
Modalis Therapeutics Corporation (Tokyo Mothers 4883) is developing precision genetic medicines through epigenetic gene modulation. Modalis is advancing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM technology which enables the locus specific modulation of gene expression or histone modification without the need for double- stranded DNA cleavage, gene editing or base editing. Modalis is headquartered in Tokyo with laboratories and R&D facilities in Cambridge,
11 to 50 staff
Setsuro Tech Inc
Setsuro Tech Inc. is a biotech startup that originated from Tokushima University and was founded in 2017. The company's mission is to "create industries that solve your and the planet's problems by harnessing from the potential of living organisms". Our company provides innovative genome editing technology and contributes to the advancement of industry and human health and well-being. We use proprietary technologies to provide contract genome editing R&D services to researchers in academia and industry. Our goal is to provide genome-edited organisms broadly available to society and to advance the genome editing industry. The name of our service, PAGEs, stands for Platform App(lication) using Genome Editing by Setsuro Tech. We named it with the idea that "genome editing will add new pages to all industries worldwide and bring about a revolution in the genome editing industry". With PAGEs, Setsuro Tech's genome editing technology can be used to develop new traits in a wide range of species and produce useful and valuable substances. Regardless of the size of the company or the scope of the business or industry, Setsuro Tech's PAGEs are creating breakthroughs in current production systems and providing solutions to social and environmental problems.
11 to 50 staff
Chiome Bioscience
Chiome Bioscience, Inc. is a biotechnology company established in 2005 that specializes in the R&D of antibody drug discovery and technology. One of our major businesses is the drug discovery business, and we are promoting R&D of antibody drug pipelines with the aim of licensing them to pharmaceutical companies. We also have another business, the drug discovery support business, where we develop partnerships and contract services with pharmaceuticals, diagnostics, biotechs, and academic institutions, utilizing our own antibody generation (ADLib® system) and optimization technologies, and protein expression technologies.
51 to 200 staff
Heartseed Inc
Heartseed Inc, a pioneering clinical-stage biotech company based in Tokyo, is at the forefront of developing groundbreaking treatments for severe heart conditions. Our cutting-edge approach involves utilizing stem cells to craft cardiomyocyte spheroids—tiny heart cell clusters. These clusters are surgically transplanted into the heart to enhance its functionality.
11 to 50 staff
Milaboratories
We're transforming the way biologists turn data into discoveries. Founded by scientists, our mission is to democratize advanced computational tools for researchers in oncology, immunology, and infectious diseases. By bridging the gap between biology and bioinformatics, we empower scientists to innovate without technical barriers. Our software, Platforma, turns raw NGS data to insights in mere hours through an intuitive interface that eliminates the coding bottleneck. Our technology is built on MiXCR—the gold standard for immune profiling, trusted by 47 of the top 50 research institutions and 8 of the top 10 pharmaceutical companies worldwide.
11 to 50 staff
Pfi Research And Development
Pharma Foods International Co Ltd is a global company based out of Japan.
201 to 500 staff
Tomy Digital Biology Co., Ltd
TOMY Digital Biology is a spun off company from TOMY Seiko in 2001. It has two functions, Import & Export. One department imports unique life science research products from other countries and distributes to Japan market. And the other department exports TOMY products to other countries.
11 to 50 staff
Avida Health Pte Ltd
Avida Health provides innovative science-based functional health solutions for the nutraceutical industry. With strong partners around the world, Avida is equipped with supply chains for raw materials, finished products and one-stop marketing solutions. We are committed to supporting our clients in APAC by bridging the gap between markets, for a shared mission of improving the quality of life for consumers around the world.
51 to 200 staff
Cj Partners Inc
CJ PARTNERS, Inc. is a Tokyo-based life science consultancy and CRO specializing in regenerative medicine but with broad experience across other technologies including biologics and medical devices. We offer start-to-finish services from market analysis to IND/IMPD/CTN submission, to clinical operations support. Additionally, we provide investment support with Japanese investors. Strategic Advisory CJP understands that detailed information regarding the Japanese market is often hidden behind linguistic barriers. We collect primary and secondary data to paint an analytical landscape of the Japanese market to drive your clinical and commercial decisions in Japan. Additionally, we can spearhead your discussions with strategic partners from licensing to manufacturing and everything in between. Regulatory Advisory CJP has conducted more than 30 consultations with the PMDA for regenerative medicine products across multiple indication areas, administration methods, and mechanisms of action. We also processed the first Accreditation Certificate of a Foreign Cell Processor for a biotech outside of Asia. Clinical Operations CJP understands and has extensive experience with the unique challenges facing the delivery and administration of cell and gene therapies, whether autologous or allogeneic. CJP has designed multiple trials for regenerative medicine products, whether administered alone, in combination with an approved drug, or in combination with an unapproved medical device. Investor/VC Advisory Relatively little known outside of Japan, there are opportunities for investment from Japanese VCs, corporate venture funds. and privately wealthy individuals with interests in the biotech and life science space. CJP has a strong network of investors who have come to depend on CJP to introduce unique opportunities.
1 to 10 staff
Eurofins Genomics
Eurofins Genomics was founded in 1990 and is part of the Eurofins Scientific Group, a Life Science Company with laboratories in 61 countries and employees. We are an international provider of genomic services around the core business lines next generation sequencing, genotyping, gene expression, custom DNA sequencing, oligonucleotides, siRNA and gene synthesis. Our services are tailored for pharma, diagnostics, agriculture, food, biotechnology and research applications worldwide. Imprint: Privacy Note:
201 to 500 staff
Hekabio K.K
We are an asset-light, emerging commercial-stage biopharma and MedTech venture that in-license early, de-risked assets to commercialize in Japan and the APAC region.
11 to 50 staff
Reprocell
REPROCELL supports nearly the entire workflow of stem cell research and pre-clinical drug development. Our unique portfolio includes access to human tissues (BioServe) and human tissue testing (Biopta), in addition to stem cell culture media, reprogramming technologies, reagents, and iPSC-derived cell types (Stemgent). With our deep knowledge of stem cell biology, bioengineered (3D) tissue models (Alvetex) cell differentiation, and pharmacology, REPROCELL is a recognized leader in cutting-edge tools and services to accelerate regenerative medicine and drug development. The newly formed REPROCELL Medical business unit is developing a suite of reagents and services to meet the growing need for clinical-grade products and services that are appropriate for regenerative medicine. In addition, our labs offer diagnostic services for a variety of tests related to tissue compatibility and other biomarkers. And finally, REPROCELL also offers a GMP iPSC master cell bank manufacturing REPROCELL went public on the Japan JASDAQ in June 2013. Stemgent, BioServe and Reinnervate became parts of REPROCELL in 2014. Biopta was then acquired in 2015.
51 to 200 staff
